Financial Performance Overview

Pfizer Inc. disclosed its first-quarter financial results for the fiscal year 2025, revealing an 8% decrease in revenue, totaling $13.7 billion. The company also experienced a 5% decline in net income, which settled at $2.97 billion, alongside a similar drop in diluted earnings per share (EPS) to $0.52.

Leadership's Perspective

David Denton, Pfizer's Chief Financial Officer, commented on the results, stating, "Our commitment to operational efficiency and financial discipline is yielding positive outcomes for our bottom line. We are currently on track to meet the upper range of our 2025 Adjusted diluted EPS guidance."

Market Reaction

Following the announcement, Pfizer's shares saw a modest increase of 0.65% in premarket trading, indicating a cautiously optimistic response from investors.